Document:

Exhibit 10.22

 

NON-EXCLUSIVE
DISTRIBUTION AGREEMENT FOR REGION OF

 

NEW
JERSEY (NORTHEAST USA)

 

DURATION:
12-Month (“1 Year”) Agreement

 

This
Amended and Restated Comprehensive Distribution Agreement (this “Agreement”) is made effective as of April 30, 2019
by and between Tauriga Sciences Inc (OTCQB: TAUG) (“TAUG” or “Tauriga”), a Florida corporation,
with a principal address of 555 Madison Avenue, 5th Floor New York, NY 10022 and Sai Krishna LLC (“SKL”), a
New Jersey corporation (engaged in distribution, marketing, and fulfillment of products —mainly to the spirits industry
and convenient stores), with its mailing address at 27 Wingate Drive // Livingston, NJ 07039.

 

W
I T N E S S E T H:

 

WHEREAS,
Tauriga is engaged in the manufacture, sale and distribution of a CBD Infused Chewing Gum Product Line (branded as Tauri-Gum TM)
(the “Products”) initially focusing on the New Jersey & Northeast Region of USA (specifically:
spirits stores, convenient stores, pharmacies, and other varying types of prospective new retail and wholesale customers) (as
defined below);

 

WHEREAS,
Tauriga is the owner or exclusive United States licensee, with authority to sublicense, of the trademarks listed on Exhibit A
hereto, and all service marks, designs, logos, trade names, advertising, commercial symbols and slogans used in connection with
Products (as defined below) (collectively or separately, the “Trademarks”) for the Products and/or such other
products that may become subject to this Agreement;

 

WHEREAS,
SKL is engaged in the management of a large number of spirits stores in New Jersey and has extensive distribution relationships
throughout the Northeast USA as well as Asia (Introductions have already been made to top affiliates at a global Asia based E-Commerce
Giant).

 

WHEREAS,
Tauriga and SKL have agreed that the Date of Execution shall be defined as: April 30, 2019.

 

In
consideration of the matters described above, and of the mutual benefits and obligations set forth in this agreement, the parties
agree as follows:

 

I.
RIGHT TO DISTRIBUTE.

 

1.
Tauriga, as the owner and/or exclusive licensee of the Trademarks and all of the other proprietary trade dress, package, designs,
logos related thereto (the “Other IP” Inclusive “USPTO filed Trademark for Tauri-GumTM”
filed for by Tauriga Sciences Inc. during December 2018) in and to the Products and Tauriga hereby grants to SKL a non-exclusive
right to distribute the Products under the terms of this Agreement in the NJ and Northeast Region of USA.

 

2.
Tauriga will contemplate granting to SKL an exclusive license to SKL to market and distribute its Tauri-GumTM
product line — for the NJ market at a later time, should both parties deem it in the best interests of
all parties (by mutual Agreement).

 

3.
Tauriga shall make inventory available to SKL, as requested by SKL to fulfill orders. All net revenue earned & realized by
Tauriga shall be deposited into Tauriga’s dedicated Revenue Intake ACCT at TD Bank.

 

4.
The parties (Tauriga and SKL) acknowledge and agree that the initial target customers shall be spirits stores, convenient
stores, pharmacies, etc. that believe that a legal CBD Infused Supplement Gum may be a desirable option for some patients.
Tauriga makes the following point(s) clear: The Company shall NOT EVER make any medical claims or treatment claims
with respect to this product — it is simply characterized and classified as a
SUPPLEMENT CHEWING GUM containing 10mg of CBD Isolate per serving ( 1 serving — 1
piece of Gum).

 

    	 

    	 

    

 

II.
SKL’s OBLIGATIONS

 

1.
SKL shall use reasonable efforts to promote the sale of Products in the NJ and Northeast Region of USA Market and to maintain
a business organization and equipment necessary to function properly in the manufacture (Tauriga’s responsibility), sale
and distribution of Products. SKL may engage such subdistributors, agents or other third parties to assist it in the performance
of this Agreement as SKL deems appropriate; provided that SKL shall be responsible for the conduct and cost of the same.

 

2.
SKL will provide to Tauriga detailed sales reports showing, by customer on a monthly basis: monthly depletions by Product, sales
by channel/accounts and monthly ending inventory

 

3.
SKL will store, transport and deliver Products at appropriate temperatures in the IRM storage facility, so as to maintain the
high quality of the Products

 

4.
SKL will provide supplemental material to potential customers — so long as such material(s) are approved by Tauriga (as
well as Tauriga s specialized CBD Counsel) for the legal protection of all parties.

 

5.
SKL shall maintain inventory levels (or notify Tauriga of its likely inventory needs) of Products reasonably necessary to satisfy
expected demand.

 

6.
SKL shall materially comply with all laws, rules, regulations, requirements, orders and ordinances now in effect of which may
hereafter be enacted or promulgated applicable to its operations or obligations under this Agreement.

 

7.
SKL covenants, warrants and represents to Tauriga that it is free to enter into this Agreement and is not and shall not be under
any obligation, written or otherwise, to any other party which would prevent SKL from complying with all the terms and conditions
of this Agreement.

 

III.
TAURIGA OBLIGATIONS.

 

1.
Marketing Support. SKL and Tauriga shall from time to time during the term of this Agreement, no less frequently as annually,
mutually determine promotional and marketing programs and expenditures to be undertaken by Tauriga to service and support the
growth and maintenance of sales in the NJ and Northeast Region of USA (each, a “Support Budget”). In this regard,
the parties covenant, agree and acknowledge that the cost of any marketing, advertising and promotional fees incurred by SKL on
behalf of Tauriga shall be split as follows:

 

(a)
Fixed fees, i.e., advertising, circular fees
— (BY Mutual Agreement);

 

(b)
all reset costs —
(BY Mutual Agreement);

 

(c)
all variable fees and any other costs, including
all off-invoice, promos and bill-backs — (BY Mutual Agreement).

 

2.
Materials to be Furnished by Tauriga. Tauriga shall furnish to SKL technical and sales promotional materials, brochures,
bulletins, and specification data on Products from time to time. Such materials will be furnished in reasonable quantities at
no cost to SKL.

 

3.
Training. SKL agrees to make available to Tauriga appropriate personnel at reasonable times and places for training on
the Products and distribution techniques preferred by Tauriga. Such training will be provided by Tauriga at Tauriga’s expense,
to assist SKL to fulfill its obligations under this Agreement.

 

    	-2-

    	 

    

 

4.
Intellectual Property. During the Term, Tauriga hereby grants to SKL a limited, non-transferrable, non-exclusive license
to use the Trademarks and Other IP to SKL solely for use on and in connection with the advertising, promotion, sale and distribution
of the Products in the NJ and Northeast Region USA Markets. Tauriga shall have the right to use SKL’s name and logo on Tauriga’s
website for the purpose of identifying SKL as a distributor of the Products

 

5.
Tauriga shall fill promptly all orders from SKL for Products and for other items to be provided by Tauriga hereunder.

 

6.
Tauriga shall promptly pay or credit to SKL’s account, when due, not less frequently than monthly, all approved and verified
credits, discounts, allowances, incentive payments, bill backs or other reimbursements due SKL pursuant to any program to which
the parties may agree.

 

7.
Tauriga represents and warrants that:

 

(a)
the Products upon delivery to SKL,

 

(i)
shall be pure and wholesome, fit for human use,
merchantable and free from all defects,

 

(ii)
shall, in all instances, comply with all applicable
Federal, state or local laws and regulations, in all respects, including without limitation, beverage quality, labeling, identity,
quantity, packaging, and returnable container or deposit requirements;

 

(iii)
shall not be adulterated and misbranded within
the meaning of those terms under the Federal Food, Drug and Cosmetic Act, as amended, and shall not be an article or articles
which may not, under the provisions, of said Act, be introduced into interstate commerce;

 

(iv)
shall not be adulterated or misbranded within
the meaning of the Federal Insecticide, Fungicide, and Rodenticide Act, the Federal Hazardous Substances Act, or any applicable
state act or any other applicable Federal, state, or local law or regulation; and

 

(v)
when delivered to SKL, shall have a remaining
shelf life of not less than twelve (12) months, the expiration of which shall be clearly marked on the outside of all cartons
and pallets;

 

(b)
it is the owner or exclusive U.S. licensee of
the Trademarks and Other IP, that it has the right to license the Trademarks and Other IP to SKL throughout the Term of this Agreement,
and that SKL’s use of the Trademarks and Other IP as provided by this Agreement will not infringe or violate the rights
of any third party; and

 

(c)
it is free to enter into this Agreement and is
not under any obligation, written or otherwise, to any other party which would prevent Tauriga from complying with all the terms
and conditions of this Agreement

 

(d) Tauriga
shall replace all Products that, at the time and place of delivery, do not meet the requirements of Section III(7) above, at
Tauriga’s expense, including the amount of SKL’s laid-in cost, at SKL’s option. Tauriga shall also
reimburse SKL for all of SKL’s incidental expenses incurred as a
consequence of such Products failure to comply with Section III(7) above (including but not limited to Products in the hands
of SKL or of the retail trade that have purchased such product from SKL if such
Products did not conform to the requirements of Section III(7)) or as a consequence of any other fault of Tauriga; provided
that Tauriga shall not be liable for any of the same to the extent they arise for the actions or inactions of SKL or
the retail trade. The foregoing shall not be construed to entitle SKL to recover lost profits or other consequential damages
resulting from the failure of Products to conform to the requirements of Section III(7) other than as expressly set forth
above

 

    	-3-

    	 

    

 

(e)
Tauriga shall materially comply with all laws,
rules, regulations, requirements, orders and ordinances now in effect or which may hereafter be enacted of promulgated applicable
to its operations or obligations under this Agreement.

 

IV.
CONSIDERATION.
In addition to any other amounts due to SKL hereunder, Tauriga shall pay and/or deliver the following:

 

1.
Retention of Neelima Lekkala as Regional Sales Vice President. In consideration for the inherent market leverage afforded
by SKL’s extensive existing relationships with dozens of spirits stores, convenient stores, pharmacies, wholesalers, etc.
etc. in the NJ and Northeast Region USA Markets, Tauriga has agreed to assist SKL’s efforts — with the hiring of Neelima
Lekkala (“Mrs. Lekkala”) as Vice President (“VP”) Regional Sales & Marketing. There will be a separate
agreement provided to Mrs. Lekkala formalize this arrangement. Her Compensation will be: 250,000 shares of TAUG (fully earned
and vested upon execution of her SPECIFIC agreement — which is, of course, separate from this one), 30% cash commission
of the total gross sales that Mrs. Lekkala generates (through the sale of Tauri-Gum product line), and she is entitled to cash
reimbursement from the Company (once invoiced) for activities directly relating to the sale of Tauri-Gum.

 

2. Restricted Stock.
1) Tauriga shall issue and deliver FIVE HUNDRED Thousand (500,000) shares of its unregistered, common stock (the “TAUG
Shares”) to SKL’s Managing Director, Mr. Mahesh Lekkala (“Mr. Lekkala”) personally. These 500,000
personal shares to Mr. Lekkala are fully earned and vested upon execution of this Agreement (for services rendered by Mr. Lekkala
since March of 2019). 2) A second issuance of FIVE HUNDRED Thousand (500,000) shares to be issued directly to SKL. This 2nd
500,000 shares issuance, shall be administered as follows: 250,000 shares to be issued to SKL upon execution this Agreement
and the balance (or final 250,000 shares) to be issued 90 days subsequent to the execution of this Agreement or August 1st,
2019). Though some shares of Tauriga’s common stock (the “Float”) are publicly tradable on the OTCQB under
the symbol “TAUG”, these TAUG Shares to be issued hereunder are not registered for resale and thus the transferability
of such shares is “restricted” to certain “exempt transactions” under the Securities Act of 1933, as amended
(the “Securities Act”), including, most notably the safe harbor sale requirements set forth in Rule 144 promulgated
under the Securities Act. SKL, represents and warrant that it is an “accredited investor” as such term is defined
by the Securities Act. TOTAL ISSUANCE SET FORTH HEREIN: 1,000,000 shares of TAUG common Stock (500,000 shares payable to Mr. Lekkala
within 10 business days of April 30, 2019 / 250,000 shares payable to SKL within 10
business days of April 30, 2019 / and 250,000 shares payable to SKL within 10 business
days of August 1, 2019).

 

SKL
reserves the right to subjugate this issuance into smaller issuances (aggregating 500,000 TAUG Shares), to any 3rd parties (individual
or corporate that it sees fit). This share issuance shall occur within thirty (10) days from date of execution of this Agreement
(however for the purpose of Rule 144, shall revert to or tack back to the date at which this Agreement is mutually executed and
deemed “Effective as of that date”). If the Subjugation Instructions or Specific Issuance Instructions have not been
provided to Tauriga within thirty (10) days from date of execution, then the Tauriga commits to issue these 500,000 shares (as
expressed in the terms above) within ten (10) business days of the date on which it RECEIVES the specific issuance instructions
from IRM.

 

    	-4-

    	 

    

 

V.
PRODUCT COST —
ORDERING PROCEDURES

 

1.
Tauriga has the absolute right to determine what SKL will be charged for each SKU of Product. Tauriga agrees that such pricing
will also be fair and ethical — comparatively to other concurrent business (being transacted in other Markets) by the Company.
However, Tauriga acknowledges that there may be a variance in pricing —depending on each individual circumstance

 

2.
Tauriga will give SKL no less than sixty (60) days prior written notice of its intention to change the Cost of any individual
SKU of Products

 

3.
The payment terms are: SKL has 30 days (from the receipt of customer payment) to transfer all appropriate revenue (portion contractually
owed to Tauriga) to the Company —to its dedicated TD Bank Revenue Intake ACCT.

 

4.
SKL shall order Products from Tauriga from time to time using the purchase order form (to be sent to SKL via email), or such other
form acceptable to the parties. Tauriga shall pay all freight charges for the sale of Products that are delivered to SKL storage
facility in NJ or at any other location it may designate within or without the SKL Market.

 

5.
Orders may be placed by fax or by telephone; however, if by telephone, a confirming fax must be sent within 24 hours and referencing
the prior telephone call so as to avoid duplicate orders. All orders placed by SKL for Products during the term of this Agreement
shall be subject to Tauriga’s acceptance and the terms of this Agreement. Orders cannot be altered by a different purchase
order form used by SKL or any other party.

 

VI.
TERMINATION

 

1.
Subject to Section VI(5) below, either party Shall have the right to terminate this Agreement upon the other party’s failure
to perform any of its material obligations contained in this Agreement, provided however that the non-breaching party shall first
give notice to the breaching party (within ten (10) days of knowledge of the breach) of each such failure and the breaching party
shall have twenty (20) days after receipt of each such notice to cure such failure. If such breach is not cured within such period,
the non-breaching party may terminate this Agreement and seek any other remedies available to it under law or equity. Notwithstanding
the foregoing, in the case of a breach in the payment for Products (not in reasonable dispute by SKL), SKL shall have only five
(5) days after receipt of notice to cure such failure, provided, that, SKL will only be afforded a maximum of two (2) opportunities
to cure payment defaults during each calendar year of the term of this Agreement.

 

2.
In addition, if either Party shall file a voluntary petition in bankruptcy, be declared bankrupt, make an assignment for the benefit
of creditors, or suffer the appointment of a receiver or trustee of its assets or is declared insolvent, that party shall be in
breach of a material obligation of this Agreement, and the non-breaching Party may immediately terminate this Agreement upon written
notice to the breaching Party.

 

3. Except for Section
VI(5) below, nothing contained herein shall be deemed to limit either Party’s right to obtain damages or equitable relief
if either Party shall breach its obligations under this Agreement. All remedies shall be cumulative and are intended to be
and shall be non- exclusive.

 

4.
Subject to Section VI(5) below, Tauriga may terminate this Agreement without cause, in its sole discretion, at any time upon sixty
(60) days advanced written notice to SKL.

 

    	-5-

    	 

    

 

5.
Payout.

 

(i)
The Payout shall be due within ninety (90) days
of the effective date of such termination. The Payout shall be net of any sums due to Tauriga as of the effective date of the
termination of the Agreement.

 

(ii)
The parties agree that in the event of such a
termination, it would be difficult to calculate SKL’s damages and the liquidated damages set forth in this Section VI(5)
are reasonable and do not constitute a penalty. SKL hereby waives to the fullest extent permitted by law, any and all other claims
for damages with respect to the termination of this Agreement subject to this Section VI(5) of any nature whatsoever, in consideration
for the receipt of the Payout.

 

6.
The parties acknowledge and agree that this Agreement may be terminated only in accordance with the terms of this Section VI and
Section XII. Any termination not permitted hereunder or under Section XII shall be deemed null and void.

 

VII.
IRM AS AN INDEPENDENT CONTRACTOR. SKL
and Tauriga shall remain independent contractors and nothing herein shall be interpreted as the parties hereto acting in concert
or as joint ventures or partners. Except as specifically set forth herein, SKL and Tauriga do not convey to each other any property
interest in the other’s corporate name, Trademarks or intellectual property. SKL has not paid nor agreed to pay any fee
or other consideration for the rights conferred on it hereby, and agrees that it is not a franchisee within the meaning of, and
hereby expressly waives, to the fullest extent permitted by law, the benefits of and any claim under, any statute or rule regulating
franchises, distribution agreements or similar matters, or any so- called franchisee or distributor protection, or business opportunity
or dealership, laws

 

VIII.
ASSIGNMENT.
This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of each party. This Agreement
is not assignable by either party without the prior express written consent of the other party, and any purported assignment without
such consent shall be null and void. Notwithstanding the foregoing, SKL may assign this Agreement to a subsidiary of or other
affiliated entity in common control with SKL without Tauriga’s consent upon written notice to Tauriga of such assignment,
so long as SKL remains primarily liable for its obligations

 

IX.
INDEMNIFICATION

 

1.
SKL shall indemnify, hold harmless and defend Tauriga, its affiliates and their respective officers, directors and employees from
any and all loss, liability, claim, damage, including but not limited to, claims of injury or death to person or damage to property,
and expenses (including reasonable attorney’s fees) which they, of any of them, may suffer or incur as a result or arising
out of the distribution or other activities of SKL under this Agreement including any intentional or negligent act/or omission
to act by SKL of any of its employees, agents officers or directors.

 

2.
Tauriga shall indemnify, hold harmless and defend SKL, its affiliates and their respective officers, directors and employees from
any and all loss, liability, claim, damage, including but not limited to, claims of injury or death to person or damage to property,
and expenses (including reasonable attorney’s fees) which they, or any of them, may suffer or incur as a result or arising
out of the breach of any representation of obligation under this Agreement, and/or with respect to the Products, or the manufacturing,
distribution or other activities of Tauriga under this Agreement, including any intentional or negligent act/or omission to act
by Tauriga or any of its employees, agents, officer of directors

 

    	-6-

    	 

    

 

3.
In any claim for indemnification under this Agreement, the party seeking indemnification (the “Indemnitee”)
shall give written notice to the other party against which such indemnification is sought (the “Indemnitor”) with
reasonable promptness after notice of any claim or suit involving, of which could involve, an indemnifiable claim under this
Agreement. Notwithstanding anything to the contrary provided in this Agreement, in any action in which such third party
claims are asserted against the Indemnitee (whether or not such claim is covered by insurance), the Indemnitee shall assert
his, her or its right of indemnification against the Indemnitor in that action, by whatever procedural options are available
to the Indemnitee. If the Indemnitor has acknowledged in writing its obligation to indemnify the Indemnitee in respect of
third-party claim, the Indemnitee shall not settle of otherwise compromise such claim without the prior written consent of
the Indemnitor, which consent shall not be unreasonably withheld, unless this condition violates the provisions of the
Indemnitor’s liability insurance policy. The parties shall cooperate with one another in the defense of any
indemnifiable claim.

 

X.
INSURANCE. During
the term of this Agreement Tauriga shall provide, and keep in force, at its sole expense, a product liability insurance policy,
with limits of liability of not less than $3,000,000 for product liability claims (insurance binder for $3,000,000 officially
completed on Friday April 26, 2019), which shall name the other party as an additional insured. Such policy shall provide that
it may not be cancelled without at least thirty (30) days prior written notice to each party as the case may be. If at any point
in this Agreement, said policies lapses on with respect to any Products manufactured or supplied to SKL for distribution, the
lapse will be considered a material breach.

 

XI.
AUTHORITY.
The undersigned persons executing this Agreement hereby certify that they are duly authorized and empowered by the governing board
of their respective company or corporation, and the articles and bylaws and/or operating agreement, as applicable, thereof, to
execute and deliver this Agreement.

 

XII.
FORCE MAJEURE

 

1.
A party’s obligation hereunder shall be suspended if such party is prevented from performing its obligations as a result
of fire, flood, explosion, accident, breakdown of machinery, product tampering by third parties, governmental acts, laws or regulations
(other than government action in response to public health violations by such party), war, terrorism, labor difficulties, any
act of God of any other cause not within such party’s control, which, by the exercise of reasonable due diligence, such
party is not able to avoid of overcome within a reasonable period of time (each, a “Force Majeure”).

 

2.
If SKL is the party that is unable to perform its obligations under this Agreement during the event of Force Majeure, upon the
occurrence of a Force Majeure event, SKL shall assess in good faith, the projected duration of the Force Majeure event. If SKL
reasonably anticipates the duration will be sixty (60) days or less, SKL will notify Tauriga in writing of the anticipated duration,
and Tauriga may distribute its products through another distribution channel. Tauriga shall be required to resume distribution
of its products through IRM seven (7) days after SKL notifies Tauriga in writing that SKL is able to commence its distribution
operations.

 

3.
Notwithstanding any other provision of this Agreement, if a Force Majeure event continues for more than ninety (90) days, the
party whose performance is not impaired by such Force Majeure event may terminate this Agreement upon written notice to the other
party, and such termination shall be with cause

 

XIII.
WAIVER.
Failure of either party at any time to require performance by the other party of any provision of this agreement shall in no way
affect the full fight to require such performance at any time thereafter. The waiver of either party to any provision of this
Agreement shall not be taken or held to be a waiver of any succeeding breach of such provisions or as a waiver of the provision
itself.

 

    	-7-

    	 

    

 

XIV.
GOVERNING LAW; JURISDICTION.
The parties agree that this Agreement shall be governed by, construed, and enforced in accordance with the laws of the State of
New York, without regard to principles of conflicts of laws. EACH OF THE PARTIES CONSENTS THAT ANY LEGAL ACTION OR PROCEEDING
AGAINST IT UNDER, ARISING OUT OF OR IN ANY MANNER RELATING TO THIS AGREEMENT, SHALL BE BROUGHT EXCLUSIVELY IN ANY COURT OF THE
STATE OF NEW YORK OR IN THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, IN EACH CASE, IN THE COUNTY OF
NEW YORK. EACH OF THE PARTIES EXPRESSLY AND IRREVOCABLY CONSENTS AND SUBMITS TO THE PERSONAL JURISDICTION OF ANY OF SUCH COURTS
IN ANY SUCH ACTION OR PROCEEDINGS. EACH OF THE PARTIES AGREES THAT PERSONAL JURISDICTION OVER IT MAY BE OBTAINED BY THE DELIVERY
OF A SUMMONS (POSTAGE PREPAID) IN ACCORDANCE WITH THE PROVISIONS OF SECTION XX OF THIS AGREEMENT. ASSUMING DELIVERY OF THE SUMMONS
IN ACCORDANCE WITH THE PROVISIONS OF SECTION 19 OF THIS AGREEMENT, EACH OF THE PARTIES HEREBY EXPRESSLY AND IRREVOCABLY WAIVES
ANY ALLEGED LACK OF PERSONAL JURISDICTION, IMPROPER VENUE OF FORUM NON CONVENIENS OR ANY SIMILAR BASIS. EACH PARTY
WAIVES TRIAL BY JURY IN ANY PROCEEDING HEREUNDER.

 

XV.
ARBITRATION. All
disputes under this Agreement that cannot be resolved by the parties shall be submitted to arbitration under the rules and regulations
of the American Arbitration Association. Either party may invoke this paragraph after providing thirty (30) days’ written notice
to the other party. All costs of arbitration shall be divided equally between the parties. Any award may be enforced by a court
of law.

 

XVI.
PRESS RELEASES. SKL
acknowledges that Tauriga may be required to issue press releases from time to time as a reporting company subject to the requirements
of the Securities Exchange Act of 1934 Act (the “34 Act”) regarding material events relating to any matter directly
or indirectly pertaining to the Agreement, the results therefrom and/or the course of conduct of the Parties relating thereto.
In this regard, Tauriga acknowledges and agrees that it shall not issue any press release referring, directly or indirectly, to
the Agreement, SKL and/or any of its affiliates, without the prior written approval of SKL.

 

XVII.
ENTIRE AGREEMENT. This
Agreement shall constitute the entire agreement between the parties and any prior understanding or representation of any kind
preceding the date of this agreement shall not be binding upon either party except to the extent incorporated in this Agreement.

 

XVIII.
MODIFICATION OF AGREEMENT. Any
modification of this Agreement of additional obligation assumed by either party in connection with this Agreement shall be binding
only if evidenced in writing and signed by each party of an authorized representative of each party.

 

XIX.
EFFECT OF PARTIAL INVALIDITY. The
invalidity of any portion of this Agreement will not and shall not be deemed to affect the validity of any other provisions. In
the event that any provision of this Agreement is held to be invalid, the parties agree that the remaining provisions shall be
deemed to be in full force and effect as if they had been executed by both parties subsequent to the expungement of the invalid
provision.

 

    	-8-

    	 

    

 

XX.
NOTICES.
Any notice provided for of concerning this Agreement shall be in writing and shall be deemed sufficiently given when sent a nationally
recognized overnight courier service to the persons and address as set forth below:

 

	For
SKL:	 	SAI KRISHNA LLC (“SKL”) — a NJ Corporation
	 	 	27
Wingate Drive
	 	 	Livingston, New Jersey 07039 

Attn:
Mr. Mahesh Lekkala

 	For
Tauriga:	 	Tauriga Sciences Inc (“TAUG” or “Tauriga”) — a FLA Corporation
	 	 	555 Madison Avenue, 5th
Floor
	 	 	New
York, NY 10022
	 	 	Attn:
Seth M. Shaw, CEO

 

XXI.
PARAGRAPH HEADINGS.
The titles to the paragraphs of this Agreement are solely for the convenience of the parties and shall not be used to explain,
modify, simplify, or aid in the interpretation of the provisions of this Agreement.

 

XXII.
COUNTERPARTS AND FAX SIGNATURES.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, and all such counterparts
shall constitute a single instrument. The parties agree that a facsimile or digital signature of a party hereto shall be deemed
to be as legally effective and binding as a signed original; provided, however, any party providing a fax or digital signature
shall be required to promptly forward a signed original to any requesting party.

 

IN
WITNESS WHEREOF, the parties hereto have duly executed this Agreement the day and year first above written.

 

	 	Tauriga Sciences Inc.
	 	 
	 	By:	 
	 	Name:	Seth
    M. Shaw April 30, 2019
		Title:	Chief
    Executive Officer, SAIKRISHNA LLC.
	 	 	 
	 	By:	 
	 	Name:	Mahesh
    Lekkala - April 30, 2019
	 	Title:	President

 

    	 

    	 

    

 

EXHIBIT
A

 

TRADEMARKS

 

“TAURI-GUM”
and all associated trademarksExhibit 10.23

 

SUBSCRIPTION
AGREEMENT

WARRANTS

 

VistaGen
Therapeutics, Inc., a Nevada corporation (the “Company”)

 

Purchase
of Warrants of the Company

 

	Instructions:	Complete
        and sign this Subscription Agreement. Please be sure to initial the appropriate “Accredited Investor” category
        in Box C.

         

        A
        completed and originally executed copy of, and the other documents required to be delivered with, this Subscription Agreement,
        must be delivered to the following address:

         

        Jerrold
        Dotson

        Chief
        Financial Officer

        VistaGen
        Therapeutics, Inc.

        343
        Allerton Avenue

        South
        San Francisco, CA 94080

        (650)
        577-3600

        jdotson@vistagen.com

 

1.
Subscription. The undersigned (the “Subscriber”) hereby irrevocably subscribes for and agrees to purchase from
the Company the number of Warrants of the Company (“Warrants”) at the price and for the aggregate consideration set
forth in Box A of Section 7 below (the “Subscription Price’). Each Warrant will entitle Subscriber to purchase one
unregistered share of the Company’s Common Stock, par value $0.001 per share (“Common Stock”) (the “Warrant
Shares”) at a price of $0.50 per share, which shall be greater than the closing quoted market price per share of the Company’s
Common Stock on the Nasdaq Capital Market on the effective date (defined below) of each Subscriber’s Subscription Agreement,
(each warrant to purchase shares of Common Stock, a “ Warrant”). The Warrants shall be immediately exercisable and
will expire three years following the effective date (defined below). The Subscription Price for each Warrant shall be $0.15.
The effective date of this Subscription Agreement shall be defined as the date on which the Company receives Subscriber’s
investment funds by wire transfer or check (the “Effective Date”).

 

2.
The Subscriber acknowledges that this Subscription Agreement is subject to acceptance by the Company. The Company may also accept
this Subscription Agreement in part. The Company and Subscriber agree that if this Subscription Agreement is not accepted in full,
any funds related to the portion of this Subscription Agreement not accepted will be promptly returned to the Subscriber, without
interest,

 

3.
Subscriber Representations. Warranties and Agreements. By executing this Subscription Agreement, the Subscriber represents,
warrants and covenants (on its own behalf and, if applicable, on behalf of each beneficial purchaser for whom it is contracting
hereunder) to the Company (and acknowledges that the Company is relying thereon) that:

 

(a)
it is authorized to consummate the purchase of the Warrants;

 

(b)
it understands that the Warrants and the Warrant Shares (collectively, the “Securities”) have not been and will not
be registered under the Securities Act of 1933 (the “Securities Act”), or any applicable state securities laws, and
that the offer and sale of the Warrants to it is being made in reliance on a private placement exemption available under Section
4(a)(2) of the Securities Act and Rule 506 of Regulation
D under the Securities Act (“Regulation D”) to accredited investors (“Accredited Investors”), as defined
in Rule 501 (a) of Regulation D;

 

    	1

     

    

 

(c)
it has reviewed copies of any documents considered by it to be important in making an investment decision whether to purchase
the Warrants. In addition, it has had access to such additional information, if any, concerning the Company as it has considered
necessary in connection with its investment decision to acquire the Warrants, and it acknowledges that it has been offered the
opportunity to ask questions and receive answers from management of the Company concerning the terms and conditions of the offering
of the Warrants, and to obtain any additional information which the Company possesses or can acquire without unreasonable effort
or expense that is necessary to verify the accuracy of the information contained in any documents provided to it;

 

(d)
it has such knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of
its investment in the Warrants and is able to bear the economic risks of, and withstand the complete loss of, such investment;

 

(e)
it is an Accredited Investor acquiring the Warrants for its own account or, if the Warrants are to be purchased for one or more
accounts (“Investor Accounts”) with respect to whom it is exercising sole investment discretion, each such investor
account is an Accredited Investor on a like basis. In each case, the undersigned has completed the Accredited Investor Status
questionnaire attached hereto to indicate under which category of Rule 501 (a) the investor qualifies as an Accredited Investor;

 

(f)
it is not acquiring the Warrants with a view to any resale, distribution or other disposition of the Warrants in violation of
federal or applicable state securities laws, and, in particular, it has no intention to distribute either directly or indirectly
any of the Warrants in the U.S. or to U.S. persons; provided, however, that the holder may sell or otherwise dispose of any of
the Warrants pursuant to registration thereof under the Securities Act and any applicable state securities laws or pursuant to
an exemption from such registration requirements;

 

(g)
in the case of the purchase by the Subscriber of the Warrants as agent or trustee for any other person, the Subscriber has due
and proper authority to act as agent or trustee for and on behalf of such beneficial purchaser in connection with the transactions
contemplated hereby;

 

(h)
it is not purchasing the Warrants as a result of any general solicitation or general advertising (as those terms are used in Regulation
D under the Securities Act), including advertisements, articles, notices or other communications published in any newspaper, magazine
or similar media or broadcast over radio or television, or any seminar or meeting whose attendees have been invited by general
solicitation or general advertising;

 

(i)
neither the Subscriber nor, to the extent it has them, any of its shareholders, members, managers, general or limited partners,
directors, affiliates or executive officers (collectively with the Subscriber, the “Covered Persons”), are subject
to any of the “Bad Actor” disqualifications described in Rule 506(d)(l)(i) to (viii) under the Securities Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Subscriber has exercised reasonable
care to determine whether any Covered Person is subject to a Disqualification Event. The purchase of the Warrants by the Subscriber
will not subject the Company to any Disqualification Event;

 

    	2

     

    

 

(j)
it understands that the Securities are “restricted securities” as defined in Rule 144(a)(3) under the Securities Act
and agrees that if it decides to offer, sell or otherwise transfer the Securities, such Securities may be offered, sold or otherwise
transferred only (A) to the Company, (B) outside the U.S. in accordance with Rule 904 of Regulation S under the Securities Act,
(C) within the U.S. or to or for the account or benefit of a U.S, Person in accordance with an exemption from the registration
requirements of the
Securities Act and all applicable state securities laws, (D) in a transaction that does not require registration under the Securities
Act or any applicable U.S. state securities laws or (E) pursuant to an effective registration statement under the Securities Act,
and in each case in accordance with any applicable state securities laws in the U.S. or securities laws of any other applicable
jurisdiction; provided that with respect to sales or transfers under clauses (C) or (D), only if the holder has furnished to the
Company a written opinion of counsel, reasonably satisfactory to the Company, prior to such sale or transfer;

 

(k)
it has been independently advised as to the applicable holding period and resale restrictions with respect to trading imposed
in respect of the Securities, by securities legislation in the jurisdiction in which it resides or to which it is otherwise subject,
and confirms that no representation has been made respecting the applicable holding periods for the Securities and is aware of
the risks and other characteristics of the Securities and of the fact that the undersigned may not be able to resell the Securities
except in accordance with applicable securities legislation and regulations;

 

(l)
no person has made to the Subscriber any written or oral representations:

 

	 	 	that
    any person will resell or repurchase any of the Securities;
	 	 	 
	 	(ii)	that
    any person will refund the purchase price of the Securities; or
	 	 	 
	 	(iii)	as
    to the future price or value of any of the Securities;

 

(m)
it understands and acknowledges that, upon exercise of the Warrants in accordance with the terms therein, the Company may issue
certificates representing the Warrant Shares, which certificates shall bear the following legend or another legend of substantially
similar substance:

 

“THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT’), OR UNDER ANY STATE SECURITIES LAWS. THE HOLDER HEREOF, BY PURCHASING THESE SECURITIES, AGREES FOR THE BENEFIT OF THE COMPANY, THAT THESE SECURITIES MAY
BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED ONLY (A) TO THE COMPANY, (B) OUTSIDE THE U.S. IN ACCORDANCE WITH REGULATION
S UNDER THE SECURITIES ACT, (C) IN COMPLIANCE WITH AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN
ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, (D) IN ANOTHER TRANSACTION THAT DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES
ACT OR ANY APPLICABLE STATE SECURITIES LAWS, OR (E) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT,
AND, IN THE CASE OF (C) AND (D), THE SELLER FURNISHES TO THE COMPANY A WRITTEN OPINION OF COUNSEL OF RECOGNIZED STANDING IN FORM
AND SUBSTANCE SATISFACTORY TO THE COMPANY TO SUCH EFFECT.”

 

(n)
it consents to the Company making a notation on its records or giving instructions to any transfer agent of the Shares in order
to implement the restrictions on transfer set forth and described herein.

 

(o)
the office or other address of the undersigned at which the undersigned received and accepted the offer to purchase the Warrants
is the address listed in Box B of Section 6 below.

 

(p)
if required by applicable securities laws, regulations, rule or order or by any securities commission, stock exchange or other
regulatory authority, it will execute, deliver and file, within the approved time periods, all documentation as may be required
thereunder, and otherwise assist the Company in
filing reports, questionnaires, undertakings and other documents with respect to the issuance of the Warrants.

 

    	3

     

    

 

(q)
this subscription agreement has been duly and validly authorized, executed and delivered by and constitutes a legal, valid, binding
and enforceable obligation of the Subscriber; and

 

(r)
it is not an affiliate (as defined in Rule 144 under the Securities Act) of the Company and is not acting on behalf of an affiliate
of the Company.

 

4.
Representations. Warranties and Covenants of the Company. As a material inducement of Subscriber to enter into this Subscription
Agreement and subscribe for the Warrants, the Company represents and warrants to Subscriber, as of the date hereof, as follows:

 

(a)
Organization and Standing. The Company is a corporation duly organized, validly existing and in good standing under the
laws of the State of Nevada, has full power to carry on its business as and where such business is now being conducted and to
own, lease and operate the properties and assets now owned or operated by it, and is duly qualified to do business and is in good
standing in each jurisdiction where the conduct of its business or the ownership of its properties requires such qualification,
except where the failure to be so qualified would not have a Material Adverse Effect on the Company. “Material Adverse Effect”
means any circumstance, change in, or effect on the Company that, individually or in the aggregate with any other similar circumstances,
changes in, or effects on, the Company taken as a whole: (i) is, or is reasonably expected to be, materially adverse to the business,
operations, assets, liabilities, employee relationships, customer or supplier relationships, prospects, results of operations
or the condition (financial or otherwise) of the Company taken as a whole, or (ii) is reasonably expected to adversely affect
the ability of the Company to operate or conduct the Company’s business in the manner in which it is currently operated
or conducted or proposed to be operated or conducted by the Company; provided, however, that none of the following shall be deemed
in and of themselves, either alone or in combination, to constitute, and none of the following shall be taken into account in
determining whether there has been or will be, a Material Adverse Effect: (A) any change, event, state of facts or development
generally affecting the general political, economic or business conditions of the United States, (B) any change, event, state
of facts or development generally affecting the industry in which the Company operates, (C) any change, event, state of facts
or development arising from or relating to compliance with the terms of this Subscription Agreement, (D) acts of war (whether
or not declared), the commencement, continuation or escalation of a war, acts of armed hostility, sabotage or terrorism or other
international or national calamity or any material worsening of such conditions, (E) changes in laws or generally accepted accounting
principles (“GAAP”) after date hereof or in interpretations thereof, or (F) any matter disclosed in this Subscription
Agreement (including the schedules hereto).

 

(b)
Authority. The Board of Directors of the Company has duly authorized the execution,
delivery and performance of this Subscription Agreement by the Company, and the consummation of the transactions contemplated
hereby. This Subscription Agreement has been (or upon delivery will be) duly executed
by the Company when delivered in accordance with the terms hereof, and will constitute, assuming due authorization and execution
and delivery by each of the parties thereto, a valid and binding obligation of the Company enforceable against the Company in
accordance with its terms. The Securities, when issued, will be validly issued, fully-paid and non-assessable.

 

(c) No
Conflicts. The execution and delivery of the Agreement and Securities and the consummation of the transactions
contemplated by this Agreement and the Securities, will not (i) conflict with or result in a breach of Or a default under any
of the terms or provisions of, (A) the Company’s certificate of incorporation or by-laws, or (B) of any material
provision of any indenture, mortgage, deed of trust or other material agreement or instrument to which the Company is a party
or by which it or any of its material properties or assets is bound, (ii) result in a violation of any provision of any law,
statute, rule, regulation, or any existing applicable decree, judgment
or order by any court, federal or state regulatory body, administrative agency, or other governmental body having
jurisdiction over the Company, or any of its material properties or assets or (iii) result in the creation or imposition of
any material lien, charge or encumbrance upon any material property or assets of the Company or any of its subsidiaries
pursuant to the terms of any agreement or instrument to which any of them is a party or by which any of them may be bound or
to which any of their property or any of them is subject except in the case of clauses (i)(B), (ii) or (iii) for any such
conflicts, breaches, or defaults or any liens, charges, or encumbrances which would not have a Material Adverse
Effect.

 

    	4

     

    

 

(d)
No Solicitation. The Company represents that it has not paid, and shall not pay, any commissions or other remuneration,
directly or indirectly, to any third party for the sale of the Securities. There are no brokers or other fees due with respect
to the sale of the Securities.

 

(e)
Material Disclosure. No representation, warranty or statement contained in this Section 3 or any disclosure furnished by
the Company pursuant to this Agreement or pursuant to its filings with the Securities and Exchange Commission contains or will
contain at closing hereunder any untrue statement of material fact or omits or will omit at such closing to state a material fact
necessary to make the statements therein, in light of the circumstances under which they were made, not misleading.

 

5.
Conditions to Closing.

 

(a)
The Company’s obligation to issue and sell the Warrants to Subscribers is subject to the fulfillment (or waiver by the Company)
of the following conditions:

 

(i)
Representations and Warranties. The representations and warranties made by Subscribers in this Subscription Agreement shall
be true and correct in all material respects when made, and shall be true and correct in all material respects upon issuance of
the Warrants;

 

(ii)
Accredited Investor Questionnaire. All Subscribers shall have completed and delivered to the Company the Accredited Investor
section of the Subscriber’s signature page attached hereto; and

 

(iii)
Approval of Subscribers. The Company, in its reasonable discretion, shall have approved the participation and amount of
participation of any Subscribers who are either individuals that are non-United States citizens or are entities domiciled in any
jurisdiction other than the United States.

 

(b)
Each Subscriber’s obligation to purchase the Warrants is subject to the fulfillment (or waiver by such Subscriber) of the
following conditions:

 

(i)
Representations and Warranties. The representations and warranties made by the Company in this Subscription Agreement shall
be true and correct when made, and shall be true and correct in all material respects upon issuance of the Warrants; and

 

(ii)
Compliance with Securities Laws. The Company shall have obtained all permits and qualifications required under federal
and/or state law and/or foreign law for the offer and sale of the Warrants or shall have the availability of exemptions therefrom.
Upon sale of the Warrants, the Company shall file a Form D with the United States Securities and Exchange Commission in a timely
manner as well as any “blue sky” filings required by the states in which Subscribers are located.

 

6. Legends.
Subscriber understands and agrees that the Company will cause any necessary restrictive legends to be placed upon any
instruments(s) evidencing ownership of the Warrants, together with any Other
legend that may be required by federal or state securities laws or deemed necessary or desirable by the Company.

 

    	5

     

    

 

7.
General Provisions.

 

(a)
Confidentiality. Subscriber covenants and agrees that it will keep confidential and will not disclose or divulge any confidential
or proprietary information that such Subscriber may obtain from the Company pursuant to financial statements, reports, and other
materials submitted by the Company to such Subscriber in connection with this Subscription Agreement, or as a result of discussions
with or inquiry made to the Company, unless such information is known, or until such information becomes known, to the public
through no action by Subscriber; provided, however, that a Subscriber may disclose such information to its attorneys, accountants,
consultants, assignees or transferees and other professionals to the extent necessary in connection with his or her investment
in the Company so long as any such professional to whom such information is disclosed is made aware of Subscriber’s obligations
hereunder and such professional agrees to be likewise bound as though such professional were a party hereto.

 

(b)
Successors. The covenants, representations and warranties contained in this Subscription Agreement shall be binding on
Subscriber’s and the Company’s heirs and legal representatives and shall inure to the benefit of the respective successors
and assigns of the Company. The rights and obligations of this Subscription Agreement may not be assigned by any party without
the prior written consent of the other party.

 

(c)
Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original agreement, but
all of which together shall constitute one and the same instrument.

 

(d)
Execution by Facsimile. Execution and delivery of this Agreement by facsimile transmission (including the delivery of documents
in Adobe PDF format) shall constitute execution and delivery of this Agreement for all purposes, with the same force and effect
as execution and delivery of an original manually signed copy hereof.

 

(e)
Governing Law and Jurisdiction. This Subscription Agreement shall be governed by and construed in accordance with the laws
of the State of Nevada applicable to contracts to be wholly performed within such state and without regard to conflicts of law
provisions.

 

THE
PARTIES HERETO EACH HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMIT TO THE EXCLUSIVE

JURISDICTION
OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF SOUTH SAN FRANCISCO, COUNTY OF SAN MATEO. THE PARTIES HERETO EACH AGREE
THAT ALL ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS SUBSCRIPTION AGREEMENT AND/OR THE OFFERING DOCUMENTS OR THE
TRANSACTIONS CONTEMPLATED THEREBY MUST BE LITIGATED EXCLUSIVELY IN ANY SUCH STATE OR FEDERAL COURT THAT SITS IN THE CITY OF SOUTH
SAN FRANCISCO, COUNTY OF SAN MATEO, AND ACCORDINGLY, THE PARTIES EACH IRREVOCABLY WAIVE ANY OBJECTION WHICH IT MAY NOW OR HEREAFTER
HAVE TO THE LAYING OF THE VENUE OF ANY SUCH LITIGATION IN ANY SUCH COURT.

 

Each of Subscriber and Company hereby irrevocably waive
and agree not to assert, by way of motion, as a defense, or otherwise, in every suit, action or other proceeding arising out of
or based on this Subscription Agreement and brought in any such court, any claim that Subscriber or the Company is not subject
personally to the jurisdiction of the above named courts, that Subscriber’s or the Company’s property, as applicable,
is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum or that
the venue of the suit, action or proceeding is improper.

 

    	6

     

    

 

(f)
Notices. All notices, requests, demands, claims and other communications hereunder shall be in writing and shall be delivered
by certified or registered mail (first class postage pre-paid), guaranteed overnight delivery, or facsimile transmission if such
transmission is confirmed by delivery by certified or registered mail (first class postage pre-paid) or guaranteed overnight delivery,
•to the following addresses and facsimile numbers (or to such other addresses or facsimile numbers which such party shall
subsequently designate in writing to the other party):

 

	 	(i)	if
    to the Company, to the address first set forth above.
	 	 	 
	 	(ii)	if
    to Subscriber to the address set forth next to its name on the signature page hereto.

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK]

 

    	7

     

    

 

8.
SUBSCRIPTION PARTICULARS

 

INFORMATION
IN RESPONSE TO THIS SECTION WILL BE KEPT STRICTLY CONFIDENTIAL

 

BOX
A

 

Particulars
of Purchase of Warrants

 

	 	Number
    of Warrants subscribed for:	 	250,000
    	 
	 	 	 	 	 
	 	Subscription
    Price ($0.15 X number of Warrants)	 	$37,500
    	 

 

BOX
B

 

Subscriber
Information For individual subscribers this address should be Subscriber’s primary legal residence. For entities other
than individual subscribers, please provide address information for the entity’s primary place of business. Information
regarding a joint subscriber should also be included.

 

	 	Name	Tauriga
    Sciences Inc.	 
	 	 	 	 
	 	Street
    Address	555
    Madison Avenue	 
	 	 	 	 
	 	Street
    Address (2)	5th
    Floor	 
	 	 	 	 
	 	City
    and State	New
    York, NY	 
	 	 	 	 
	 	Zip
    Code	10022	 
	 	 	 	 
	 	Contact
    Name	Seth
    M. Shaw (CEO)	 
	 	 	 	 
	 	Alternate
    Contact	Kevin
    P. Lacey (CFO)	 
	 	 	 	 
	 	Phone
    No.	(917)
    796-9926	 
	 	 	 	 
	 	Fax
    No. / E-mail Address	sshaw@tauriga.com	 
	 	 	 	 
	 	Tax
    ID # or Social Security #	30-0791746	 

 

    	8

     

    

 

BOX
C

 

Accredited
Investor Status

 

The
Subscriber represents and warrants that it is an “accredited investor”, as defined in Rule 501(a) under the Securities
Act, by virtue of satisfying one or more of the categories indicated below (please write your initials on the line next to each
applicable category):

 

	 	[  ]	Category
    1.	A
    bank, as defined in section 3(a)(2) of the Securities Act.
	 	 	 	 
	 	 	 	A
    savings and loan association or other institution, as defined in section 3(a)(5)(A) of the Securities Act, whether acting
    in its individual or fiduciary capacity.
	 	 	 	 
	 	 	 	A
    broker or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934.
	 	 	 	 
	 	 	 	An
    insurance company as defined in section 2(a)(13) of the Securities Act.
	 	 	 	 
	 	 	 	An
investment company registered under the Investment Corporation Act of 1940 or a business development company as defined in section
2(a)(48) of that Act.
	 	 	 	 
	 	 	 	A
    Small Business Investment Corporation licensed by the U.S. Small Business Administration under section 301 (c) or (d) of the
    Small Business Investment Act of 1958.
	 	 	 	 
	 	 	 	A
    plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its
    political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000
	 	 	 	 
	 	 	 	An
    employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974 if the investment decision
    is made by a plan fiduciary, as defined in section 3(21) of such
    Act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the
    employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made
    solely by persons that are accredited investors.
	 	 	 	 
	 	[  ]	Category
    2.	Any
    private business development company as defined in section 202(a)(22) of the Investment Advisers Act of 1940.
	 	 	 	 
	 	 	Category
    3.	An
    organization described in Section 501 of the Internal Revenue Code, a corporation, a Massachusetts or similar business trust,
    or a partnership, not formed for the specific purpose of acquiring the Securities, with total assets in excess of $5,000,000.
	 	 	 	 
	 	[  ]	Category
    4.	A
    director or executive officer of the Company.
	 	 	 	 
	 	[  ]	Category
        5.

         

         

        
	A
    natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of this purchase exceeds
    $1 ,000,000, excluding the value of the person’s primary residence, if any.
	 	 	 	 
	 	[  ]	Category
        6.	A
    natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with
    that person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of reaching the same income
    level in the current year.
	 	 	 	 
	 	[  ]	Category
    7.	A
    trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Securities, whose purchase
    is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D under the U.S. Securities Act.
	 	 	 	 
		[✔]	Category
    8.	An
    entity in which each of the equity owners is an accredited investor.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	9

     

    

 

SUBSCRIBER
SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT

+

 

	AGREED
    AND SUBSCRIBED	 	AGREED AND SUBSCRIBED

                                                                     SIGNATURE OF JOINT SUBSCRIBER

	 	 	 	 
	 	 	 	This
    6th day of December 2019
	By:	 	 	By:	 
	Name:	Seth
    M. Shaw	 	Name:	 
	Title
    (if any):	Chief
    Executive Officer	 	Title
    (if any):	 
	 	 	 	 	 
	TAURIGA
    SCIENCES INC.	 	 	 
	 	 	 
	Subscriber
    Name (Typed or Printed)	 	Additional Subscriber Name (Typed or Printed)

 

    	10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]